Sickle cell disease is a group of blood disorders typically inherited from a person's parents. It affects hemoglobin, a protein in red blood cells that carries oxygen throughout the body. Sickle cell disease causes red blood cells to become hard and sticky and appear in a C- or sickle shape. These sickle-shaped cells do not live as long as healthy red blood cells and also block small blood vessels. Common symptoms of sickle cell disease include anemia, swelling in hands and feet, periodic pain due to poor blood flow, and susceptibility to infections. Currently there is no universal cure for sickle cell disease but treatments are available to manage symptoms and prevent complications.

Global Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.20 Bn in 2025 and is expected to reach USD 8.81 Bn by 2032 exhibiting a compound annual growth rate (CAGR) of 15.6% from 2025 to 2032.

Key players operating in the sickle cell disease treatment market include AbbVie, Blueprint Medicines, Bristol Myers Squibb, Emmaus Life Sciences, Global Blood Therapeutics, Inc., Pfizer Inc., Novartis, Sangamo Therapeutics and others. Rising awareness about sickle cell disease through various programs organized by governments and non-profit organizations is driving more patients to seek treatment.

This is fueling the Sickle Cell Disease Treatment Market Trends. Additionally, increasing research and development investments by pharmaceutical companies for developing novel treatments for sickle cell disease is expected to give a boost to market growth over the forecast period.

Get More Insights on- Sickle Cell Disease Treatment Market